Insider Buying: IXICO (LON:IXI) Insider Acquires £4,000.48 in Stock

IXICO plc (LON:IXI) insider Mark Warne acquired 50,006 shares of the business’s stock in a transaction dated Wednesday, July 15th. The stock was purchased at an average cost of GBX 8 per share, for a total transaction of £4,000.48.

IXICO Trading Up 9.1%

Shares of LON:IXI opened at GBX 9 on Friday. The company has a quick ratio of 4.90, a current ratio of 2.83 and a debt-to-equity ratio of 5.22. IXICO plc has a 52-week low of GBX 6.26 and a 52-week high of GBX 15. The stock has a market cap of £19.71 million, a price-to-earnings ratio of -4.62, a PEG ratio of -0.38 and a beta of 0.13. The business has a 50-day moving average price of GBX 8.31 and a 200-day moving average price of GBX 8.66.

IXICO (LON:IXI) last issued its earnings results on Tuesday, May 19th. The company reported GBX (1.21) EPS for the quarter. IXICO had a negative net margin of 24.98% and a negative return on equity of 16.18%. The firm had revenue of GBX 395 million during the quarter. Equities analysts predict that IXICO plc will post -289.3584879 EPS for the current year.

IXICO Company Profile

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.

By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials.